High prescription drug costs are leaving many patients frustrated and unable to afford their medications.
Articles on Prescription drug prices
Displaying all articles
As the middlemen between drug companies and insurers, PBMs are shoo-ins as the villains behind high drug prices. But they do play a useful role in the health marketplace.
An inhaler that costs nearly $300 in the US goes for just $9 in Germany. What gives?
Congress has the power to make sure government serves the public interest. Conducting investigations is one way lawmakers do that.
Changes to Canada’s Patented Medicine Prices Review Board regulations have been postponed for a fourth time in two years as Canadians continue to pay some of the highest drug prices in the world.
Canada’s lack of pharmacare harms health in our communities, strains our health-care system and encumbers our economy. Parliament is out of excuses for not implementing a national drug plan.
Any pharmacare plan that aims to remove financial barriers to treatment and eliminate inequities should prioritize those who face the highest out-of-pocket drug costs, such as people with disabilities.
The high cost of pharmaceuticals often means only the richest patients get lifesaving medicines. As coronavirus drugs emerge, it will require hard, creative work to ensure they’re available to all.
Studies repeatedly have shown that health care in general and the high cost of drugs in particular are among the top concerns of US voters. But with coronavirus, the issue may fade from prominence.
The Trump administration’s proposal to lower drug prices focuses on discounts. A health policy scholar argues that the US could learn from Europe’s system of measuring drug value and effectiveness.
Shortages and high prices are making pharmaceuticals, often including generics, out of reach for millions of Americans.
The rising costs of generic drugs have led to outcries. In a search for solutions, four hospital systems are proposing to make drugs on their own. Could their idea work?
Top contributors
-
Associate Professor of Public Health, The Ohio State University
-
Associate Professor of Health Policy and Cancer Research, Vanderbilt University
-
Assistant Professor of Government, Smith College
-
Professor, School of Rehabilitation Therapy, Queen's University, Ontario
-
Professor of Philosophy, Binghamton University, State University of New York
-
Clinical Professor of Pharmacy Practice, University of Mississippi
-
Associate Professor of Pharmacy Administration, University of Mississippi
-
Professor of Law, Villanova University
-
Research Coordinator, Centre for Health Services and Policy Research and School of Rehabilitation Therapy, Queen's University, Ontario
-
Assistant Professor, Department of Family and Community Medicine, University of Toronto
-
Associate professor, Department of Family and Community Medicine, University of Toronto; York University, Canada; University of Sydney
-
Professor of Management, MIT Sloan School of Management
-
Wexler Professor of Management, Economics and Public Policy, Boston University